Human Tumor Stem-Cell Assay

Sydney E. Salmon, David S. Alberts, Frank L. Meyskens, Thomas E. Moon, Matti S. Aapro, James R. Eliason, Gunter E. Umbach, Gary Spitzer, Verena Hug, E. Neely Atkinson, Terry F. Plasse, Larry M. Weisenthal, Samuel Balk, Peter Selby, Ronald Buick, Ian Tannock

Research output: Contribution to journalLetter

8 Scopus citations


To the Editor: Since our group first reported on the potential clinical applications of the human tumor stem-cell, or clonogenic, assay in the Journal,1 we think some comment from us is warranted regarding the recent article by Selby et al.2 and the editorial by Von Hoff.3 We clearly agree that it is important to plate good single-cell suspensions, that drug-sensitivity criteria are still in the developmental stages,4 that some drugs may require the evaluation of various exposure times, that inappropriate drug concentrations may be misleading, that drugs requiring bioactivation present special problems, that radiation-survival curves with plateaus at.

Original languageEnglish (US)
Pages (from-to)1478-1481
Number of pages4
JournalNew England Journal of Medicine
Issue number24
StatePublished - Jun 16 1983


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Salmon, S. E., Alberts, D. S., Meyskens, F. L., Moon, T. E., Aapro, M. S., Eliason, J. R., Umbach, G. E., Spitzer, G., Hug, V., Atkinson, E. N., Plasse, T. F., Weisenthal, L. M., Balk, S., Selby, P., Buick, R., & Tannock, I. (1983). Human Tumor Stem-Cell Assay. New England Journal of Medicine, 308(24), 1478-1481.